3.0SEK
91.82 MSEK
597.54 MSEK
24.21 M
About XVIVO PERFUSION AB NPV
Sector
Industry
CEO
Christoffer Rosenblad
Website
Headquarters
Gothenburg
Employees (FY)
150
Founded
1998
ISIN
SE0004840718
FIGI
BBG00JHW7PD2
Xvivo Perfusion AB is a medical technology company. It involves in developing and marketing solutions and systems for assessing the usability of organs, and maintaining organs in good condition outside the body pending transplantation. Its products include XPS, XPS Disposable Kit, Steen Solution, Organ Chamber, Lung Cannula Set, Perfadex and Silicone Tubing Set. It operates through the Durable Goods and Non-Durable Goods segments. The Durable Goods segment includes sales and rental revenues from machines. The Non-Durable Goods segment covers sales of goods and services that are not durable goods. The company was founded by Magnus Nilsson on December 17, 1998 and is headquartered in Gothenburg, Sweden.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 0RKL is 318.5 SEK — it has increased by 1.43% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange XVIVO PERFUSION AB NPV stocks are traded under the ticker 0RKL.
XVIVO PERFUSION AB NPV is going to release the next earnings report on Apr 24, 2024. Keep track of upcoming events with our Earnings Calendar.
0RKL stock is 2.08% volatile and has beta coefficient of 0.89. Check out the list of the most volatile stocks — is XVIVO PERFUSION AB NPV there?
0RKL earnings for the last quarter are 0.10 SEK per share, whereas the estimation was 0.43 SEK resulting in a −76.91% surprise. The estimated earnings for the next quarter are 0.47 SEK per share. See more details about XVIVO PERFUSION AB NPV earnings.
XVIVO PERFUSION AB NPV revenue for the last quarter amounts to 146.61 M SEK despite the estimated figure of 156.40 M SEK. In the next quarter revenue is expected to reach 173.36 M SEK.
Yes, you can track XVIVO PERFUSION AB NPV financials in yearly and quarterly reports right on TradingView.
0RKL stock has fallen by 2.90% compared to the previous week, the month change is a 14.16% rise, over the last year XVIVO PERFUSION AB NPV has showed a 20.42% increase.
0RKL net income for the last quarter is 68.47 M SEK, while the quarter before that showed 2.28 M SEK of net income which accounts for 2.90 K% change. Track more XVIVO PERFUSION AB NPV financial stats to get the full picture.
Today XVIVO PERFUSION AB NPV has the market capitalization of 9.89 B, it has increased by 5.35% over the last week.
No, 0RKL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 0RKL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade XVIVO PERFUSION AB NPV stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 150.00 employees. See our rating of the largest employees — is XVIVO PERFUSION AB NPV on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So XVIVO PERFUSION AB NPV technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating XVIVO PERFUSION AB NPV stock shows the strong buy signal. See more of XVIVO PERFUSION AB NPV technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on XVIVO PERFUSION AB NPV future price: according to them, 0RKL price has a max estimate of 439.00 SEK and a min estimate of 340.00 SEK. Read a more detailed XVIVO PERFUSION AB NPV forecast: see what analysts think of XVIVO PERFUSION AB NPV and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. XVIVO PERFUSION AB NPV EBITDA is 78.27 M SEK, and current EBITDA margin is 11.61%. See more stats in XVIVO PERFUSION AB NPV financial statements.